# Brief Correspondence

## Serum Total Testosterone and Premature Mortality Among Men in the USA

**Richard J. Fantus**
**Cecilia Chang**
**Elizabeth A. Platz**
**Nelson E. Bennett**
**Brian T. Helfand**
**Robert E. Brannigan**
**Joshua A. Halpern**

### Article info

**Article history:**
Accepted May 13, 2021

**Associate Editor:**
Silvia Proietti

**Keywords:**
Testosterone  
Hypogonadism  
Low testosterone  
National Health and Nutrition Examination Survey  
Premature mortality

### Abstract

The relationship between testosterone and premature mortality has caused recent controversy. While previous studies have demonstrated mixed results, this is partly because of variable patient populations, different testosterone thresholds, and the use of antiquated techniques to measure serum testosterone. Using the National Health and Nutrition Examination Survey we analyzed a cohort representative of men in the USA to explore the relationship between serum testosterone and premature mortality using contemporary guidelines and testosterone measurements. We found that men with low testosterone (<300 ng/dl) were at higher risk (odds ratio 2.07, 95% confidence interval 1.30–3.32; p < 0.01) of premature death compared to men with normal testosterone. Furthermore, men with low testosterone were also more likely to have treatable comorbid conditions that were independently predictive of premature mortality. Both testosterone and these comorbid conditions are also modulated by lifestyle modifications, rendering this an important therapeutic approach in men with either or both conditions.

**Patient summary:** We explored the relationship between testosterone levels and premature death in a large US population. We found that low testosterone is associated with both premature death and related disease processes such as obesity, both of which can be initially treated with diet and exercise.

© 2021 Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The association between low testosterone (LT) and the risk of premature mortality is unclear but has significant implications for screening and treatment guidelines. Prior studies examining this association have found conflicting results, possibly owing to differences in testosterone (T) assays and LT threshold values, whereas others were limited by lack of generalizability [1–4]. To address these limitations, we used a contemporary guideline-based definition of LT to examine the association between LT and mortality in a US nationally representative cohort of noninstitutionalized men in whom serum T was previously measured without clinical indication [5].

We analyzed data from the National Health and Nutrition Examination Survey (NHANES) that were linked to the National Death Index (NDI) through December 31, 2015 using a probabilistic matching algorithm [6]. In brief, the NDI, a program of the US National Center for Health Statistics, contains information on all death records in the...
USA after 1979, submitted as statewide data approximately 11 mo after the end of the calendar year. All NHANES participants provide written consent, as described elsewhere [6].

Our analysis included all men aged 40–79 yr with available morning serum T levels (NHANES cycles 1999–2000, 2003–2004, 2011–2012, and 2013–2014). In the earlier cycles (1999–2004), one-third of all men (selected for an unrelated reason) underwent testosterone testing, whereas all eligible men were tested in later cycles [7]. Men treated with androgen deprivation therapy were excluded (Supplementary Fig. 1). Serum T was measured in eligible men via either immunoassay (1999–2000 and 2003–2004) or isotope dilution liquid chromatography and tandem mass spectrometry (2011–2012 and 2013–2014), as described elsewhere [8,9,10].

We estimated the association between LT (<300 ng/dl) and all-cause mortality using Cox proportional-hazard models [5]. To inform future guidelines, we report the age-adjusted association between LT and mortality. Covariates that conferred a risk of premature mortality were also characterized. We used $\chi^2$ tests and Student's t tests, where applicable, to analyze the association between relevant covariates and LT, including the 10-yr atherosclerotic cardiovascular disease (ASCVD) risk score used for cardiac risk stratification, which has been previously validated in NHANES [6]. Sensitivity analysis using the Cox proportional-hazard model controlled for age, body mass index (BMI), disability, history of cancer, and ASCVD was also performed. All statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA), with a two-tailed $p$ value <0.05 considered significant.

Among 1792 men aged 40–79 yr, 436 (22.11%) had LT and 153 (8.54%) died. Adjusting for age, men with LT were more likely to experience premature death (odds ratio 2.07, 95% confidence interval [CI] 1.30–3.32; $p < 0.01$; Fig. 1). Additional variables associated with premature mortality included marital status, household income, BMI, ASCVD risk, diabetes (DM), hypertension (HTN), walking disability, history of congestive heart failure (CHF), myocardial infarction (MI), and stroke.

Compared to eugonadal men, men with LT were more likely to exhibit obesity, DM, HTN, CHF, MI, walking disability, and a higher ASCVD risk (Table 1). Multivariable analysis demonstrated an independent relationship between LT and premature mortality, with a hazard ratio of 1.66 (95% CI 1.11–2.48; $p = 0.01$). There were no statistically significant differences in the proportion of specific causes of mortality among deceased men with and without LT (data not shown).

We found that US men aged 40–79 yr with LT had a higher risk of premature mortality compared to men with normal T. These data are broadly generalizable, address many limitations of previous retrospective studies, and have important clinical implications [2,3]. Unlike previous work, T measurement in male NHANES participants was not related to symptoms or other clinical indication, thereby limiting sampling bias [2].

The higher risk of premature mortality with LT supports a possible role for screening at-risk individuals even in the absence of hypogonadal symptoms. Our data indicate that men already at risk of premature death (eg, men with obesity, DM, and cardiac morbidity) are also more likely to have LT, which can exacerbate this association, and men with the aforementioned conditions would benefit the most from LT screening. This also demonstrates the importance of guideline-directed care focused on lifestyle changes, which can treat LT and associated comorbidities and ultimately reduce the morbidity and premature mortality associated with LT. The current study must be viewed within the scope of its limitations: it is an observational, time-to-event study; men only had a single T measurement (using 2 different methods); we used a nonharmonized and dichotomized T threshold of <300 ng/dl; and men were selected regardless of symptomatology [11].

![Fig. 1 – Age-adjusted Kaplan-Meier analysis of all-cause mortality for men with and without low testosterone.](image-url)
**Table 1 – Association of participant characteristics with premature mortality and morning testosterone levels in the National Health and Nutrition Examination Survey.**

| Marital status               | Patients, n (%) | p value |
|------------------------------|----------------|---------|
| T <300 ng/dl | T ≥300 ng/dl |
| Unmarried or other           | 115 (26.04) | 374 (25.18) | 0.79 |
| Married or living with a partner | 318 (73.96) | 970 (74.82) | |
| Poverty income ratio         | 0.15 |
| Below poverty line           | 719 (90.59) | 237 (10.04) | |
| At or above poverty line     | 311 (90.75) | 1014 (86.96) | |
| Body mass index              | <0.01 |
| Underweight (<18.5 kg/m²)    | 2 (0.5) | 10 (0.78) | |
| Normal (18.5–24.9 kg/m²)     | 50 (10.75) | 384 (25.56) | |
| Overweight (25–29.99 kg/m²)  | 10 (10.59) | 50 (43.8) | |
| Obese (>30 kg/m²)            | 4 (6.17) | 35 (29.86) | |
| Diabetes                     | 2 (0.5) | 2 (0.5) | <0.01 |
| Hypertension                 | 2 (0.5) | 2 (0.5) | <0.01 |
| Walking disability           | 1 (0.2) | 198 (10.46) | <0.01 |
| History of congestive heart failure | 2 (0.5) | 3 (1.2) | <0.01 |
| History of heart attack      | 2 (0.5) | 79 (5.65) | <0.01 |
| History of stroke            | 2 (0.5) | 67 (4) | 0.79 |
| 10-yr atherosclerotic cardiovasular disease risk | 0.01 |
| Low risk (<5%)               | 147 (32.02) | 497 (41.75) | |
| Borderline risk (5–74%)      | 16 (3.99) | 16 (3.99) | 14.58 |
| Intermediate risk (7.5–19%)  | 13 (3.4) | 44 (30.34) | |
| High risk (≥20%)             | 12 (3.08) | 25 (18.47) | |

**Author contributions:** Joshua A. Halpern had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Fantus, Halpern, Brannigan, Platz.

**Acquisition of data:** Fantus, Chang.

**Analysis and interpretation of data:** Fantus, Chang, Halpern, Brannigan, Platz, Helfand, Bennett.

**Drafting of the manuscript:** Fantus, Halpern, Platz.

**Critical revision of the manuscript for important intellectual content:** Halpern, Bennett, Helfand, Brannigan, Platz.

**Statistical analysis:** Chang, Platz.

**Obtaining funding:** None.

**Administrative, technical, or material support:** None.

**Supervision:** Brannigan, Bennett, Helfand.

**Other:** None.

**Financial disclosures:** Joshua A. Halpern certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

**Funding/Support and role of the sponsor:** None.

**Appendix A. Supplementary data**

Supplementary material related to this article can be found, in the online version, at doi: [https://doi.org/10.1016/j.euros.2021.05.008](https://doi.org/10.1016/j.euros.2021.05.008).

**References**

[1] [Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534–43.](http://dx.doi.org/10.1210/jc.2003-031287.)

[2] Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829–36. [http://dx.doi.org/10.1001/jama.2013.280386.](http://dx.doi.org/10.1001/jama.2013.280386.)

[3] Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007–19. [http://dx.doi.org/10.1210/jc.2011-1137.](http://dx.doi.org/10.1210/jc.2011-1137.)

[4] Morgentaler A. Testosterone deficiency and cardiovascular mortality. Asian J Androl 2015;17:26. [http://dx.doi.org/10.4103/1008-682X.143248.](http://dx.doi.org/10.4103/1008-682X.143248.)

[5] Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol 2018;200:423–32. [http://dx.doi.org/10.1016/j.juro.2018.03.115.](http://dx.doi.org/10.1016/j.juro.2018.03.115.)

[6] Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equations in predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc 2016;91:763–9. [http://dx.doi.org/10.1016/j.mayocp.2016.03.019.](http://dx.doi.org/10.1016/j.mayocp.2016.03.019.)

[7] Nyante SJ, Graubard BI, Li Y, et al. Trends in sex hormone concentrations in US males: 1988–1991 to 1999–2004. Int J Androl 2012;35:456–66. [http://dx.doi.org/10.1111/j.1365-2605.2011.01230.x.](http://dx.doi.org/10.1111/j.1365-2605.2011.01230.x.)

[8] Zhou H, Wang Y, Gatcombe M, et al. Simultaneous measurement of total estradiol and testosterone in human serum by isotope dilution liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 2017;409:5943–54. [http://dx.doi.org/10.1007/s00216-017-0529-x.](http://dx.doi.org/10.1007/s00216-017-0529-x.)
[9] Vesper HW, Wang Y, Vidal M, Botelho JC, Caudill SP. Serum total testosterone concentrations in the US household population from the NHANES 2011–2012 study population. Clin Chem 2015;61:1495–504. http://dx.doi.org/10.1373/clinchem.2015.245969.

[10] Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone corrected measurements performed by mass spectrometry methods. Steroids 2009;74:498–503. http://dx.doi.org/10.1016/j.steroids.2009.01.004.

[11] Travison TG, Vesper HW, Orwoll E, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab 2017;102:1161–73. http://dx.doi.org/10.1210/jc.2016-2935.

*Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
bDepartment of Surgery, NorthShore University Health System, Chicago, IL, USA
Department of Surgery, NorthShore University Health System, Chicago, IL, USA

*Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins, Baltimore, MD, USA

*Corresponding author. Department of Urology, Feinberg School of Medicine, Northwestern University, 676 North St. Claire Street, Chicago, IL 60611, USA. Tel. +1 312 6958146.
E-mail address: joshua.halpern2@nm.org (J.A. Halpern).

These authors contributed equally to this work.